Compare MAMA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | VYGR |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.1M | 203.6M |
| IPO Year | 2011 | 2015 |
| Metric | MAMA | VYGR |
|---|---|---|
| Price | $18.93 | $3.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $19.00 | $16.50 |
| AVG Volume (30 Days) | ★ 528.9K | 476.5K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $95,420,129.00 | $10,135,000.00 |
| Revenue This Year | $31.09 | $34.04 |
| Revenue Next Year | $16.12 | $7.92 |
| P/E Ratio | $362.60 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $7.88 | $2.83 |
| 52 Week High | $18.65 | $5.55 |
| Indicator | MAMA | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 76.00 | 52.15 |
| Support Level | $13.23 | $3.71 |
| Resistance Level | N/A | $4.29 |
| Average True Range (ATR) | 0.98 | 0.19 |
| MACD | 0.46 | 0.04 |
| Stochastic Oscillator | 99.50 | 81.25 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.